Detalhe da pesquisa
1.
Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
Rheumatology (Oxford)
; 59(10): 2774-2784, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32031665
2.
Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
Acta Derm Venereol
; 100(1): adv00006, 2020 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31620802
3.
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
N Engl J Med
; 375(4): 345-56, 2016 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27299809
4.
Points to consider for analyzing efficacy outcomes in long-term extension clinical trials.
Pharm Stat
; 17(6): 685-700, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30051580
5.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Lancet
; 386(9993): 541-51, 2015 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26072109
6.
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
J Am Acad Dermatol
; 71(6): 1176-82, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25242558
7.
Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis.
J Am Acad Dermatol
; 79(3): 593-595, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29559395
8.
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 376(9741): 595-605, 2010 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-20673995
9.
Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
Neuropsychopharmacology
; 33(7): 1603-10, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17712352
10.
Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.
Eur Neuropsychopharmacol
; 18(9): 673-81, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18559291
11.
Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.
Depress Anxiety
; 25(7): E1-11, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-17587217
12.
Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies.
Hum Psychopharmacol
; 23(6): 519-26, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18478624
13.
Implications of pain in generalized anxiety disorder: efficacy of duloxetine.
Prim Care Companion J Clin Psychiatry
; 10(3): 197-204, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18615176
14.
Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial.
Int Clin Psychopharmacol
; 22(3): 167-74, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17414743
15.
Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians.
Prim Care Companion J Clin Psychiatry
; 9(2): 100-7, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17607331
16.
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.
J Rheumatol
; 43(2): 289-97, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26669919
17.
Pain Assessment for the Dementing Elderly (PADE): reliability and validity of a new measure.
J Am Med Dir Assoc
; 4(1): 1-8, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-12807590
18.
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Obesity (Silver Spring)
; 19(1): 110-20, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20559296
19.
Path to bariatric nurse certification: the practice analysis.
Surg Obes Relat Dis
; 6(4): 399-407, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20655022
20.
An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects.
Addict Behav
; 35(3): 229-34, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19926400